Firebrick Pharma Limited (FRE.AX)
ASX
Healthcare
Drug Manufacturers - General
$0.03
▼ -9.09%
Market Cap
$7.2M
Sector
Healthcare
Industry
Drug Manufacturers - General
Beta
0.85
52-Wk Range
0.024-0.081
CEO
Peter Laurence Molloy
Country
AU
Currency
AUD
Firebrick Pharma Limited operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Melbourne, VIC, AU. The stock last traded at $0.03, down 9.09% on the session, giving a market capitalisation of $7.2M. Its beta of 0.85 implies it has historically moved less than the broad market.
Company profile
Exchange
Australian Securities Exchange
Employees
6
IPO date
2022-01-27
Headquarters
Melbourne, VIC, AU
About Firebrick Pharma Limited
Firebrick Pharma Limited, an enterprise established in 2012 and headquartered in Melbourne, Australia, is dedicated to the research, development, and market launch of Nasodine, a nasal spray treatment for the common cold, exclusively for the Australian market.
Comparable companies
Firebrick Pharma Limited is most often compared with the following Healthcare names:
More research on FRE.AX
Open full interactive analysis & DCF →